Nimai Corp Private Limited

Mounjaro 12.5mg KwikPen (Tirzepatide Injection) is used to improve blood sugar control in adults with type 2 diabetes. It works by activating GIP and GLP-1 receptors, helping increase insulin release, reduce appetite, and support weight loss. It is given once weekly by injection. Common side effects include nausea, vomiting, diarrhea, and decreased appetite. Use under medical supervision.

Mounjaro 2.5mg KwikPen (Tirzepatide Injection) is used to manage type 2 diabetes by improving blood sugar control. It works by activating GIP and GLP-1 receptors, helping increase insulin release, reduce appetite, and support weight loss. It is administered once weekly by injection. Common side effects include nausea, vomiting, diarrhea, and decreased appetite. Use under medical supervision.

Mounjaro 7.5mg KwikPen improves blood sugar control in adults with type 2 diabetes when used in conjunction with a balanced diet and regular exercise. It aids in weight loss for obese (BMI ≥30) or overweight (BMI 27 and <30) adults by increasing insulin sensitivity and reducing hunger.

Mounjaro 10mg KwikPen improves blood sugar control in adults with type 2 diabetes when used in conjunction with a balanced diet and regular exercise. It aids in weight loss for obese (BMI ≥30) or overweight (BMI 27 and <30) adults by increasing insulin sensitivity and reducing hunger.

Mounjaro (Tirzepatide) is a first-in-class dual incretin receptor agonist, acting on both GIP (Glucose-Dependent Insulinotropic Polypeptide) and GLP-1 (Glucagon-Like Peptide-1) receptors. It is used as a once-weekly subcutaneous injection for the management of Type 2 Diabetes Mellitus in adults, helping improve glycemic control alongside diet and exercise.

Tirzepatide, sold under the brand names Mounjaro and Zepbound, is an antidiabetic medication used for the treatment of type 2 diabetes and for weight loss. Tirzepatide is administered through subcutaneous injection.

MOUNJARO KWIKPEN tirzepatide 5mg solution for injection in pre-filled pen (UK) ​​MOUNJARO is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise: as monotherapy when metformin is not tolerated or contraindicated.